Elsevier at a glance
We want to make analysis easier for everyone working in science and medicine. Growing from our roots in publishing, we help you manage work efficiently so you can spend more time making breakthroughs.
Technological advancement and the data revolution have pushed the boundaries of science and medicine.
Discoveries unimaginable a generation ago are uncovered every day. At Elsevier, we recognize the potential for scientists and clinicians to find new answers, reshape human knowledge and tackle the most urgent global crises.
We want to make analysis easier for everyone working in science and medicine, enabling them to manage their work more efficiently and spend more time making breakthroughs. That's why Elsevier is evolving. Growing from our roots in publishing, we're creating analytical solutions to serve the needs of science and health.
Elsevier employs over 1,500 technologists.
of our revenue comes from digital products.
Elsevier also applies advanced machine-learning techniques that detect trending topics per domain, helping researchers make more informed decisions. Coupled with the automated profiling and extraction of funding body information from scientific articles, this process supports the whole researcher journey, from planning to execution and funding. Similarly, in health, Elsevier is developing clinical decision support applications that utilize cognitive technologies to map patient and claims data sets and large image and text content repositories.
Every tool we develop is built on trusted information.
At Elsevier, we have partnered with the scholarly community for 140 years to curate and verify knowledge. Now, as an information analytics business, we’re committed to bringing that rigor to a new generation of Elsevier platforms – especially at a time when it’s harder than ever to know what to believe.
ScienceDirect user distribution continues to expand.
In 2018, Elsevier’s article output accounted for 18% of global research output while garnering a 25% share of citations, demonstrating Elsevier’s commitment to delivering research quality significantly above of the industry average.
ScienceDirect has 16m monthly unique visitors.
1 billion articles were downloaded by researchers.
As well as enriching science, the proliferation of data brings new challenges for those striving for progress. Vast volumes of information are hard to navigate and organize, increasing the risk of critical data being overlooked.
It’s tougher to ensure the credibility of data. Research and healthcare are more complex when incorporating findings from multiple disciplines. In the globalized academic community, there is more competition than ever for jobs, students and funding.
With more than 39,000 eBooks from Elsevier, our imprints and our society partners, ScienceDirect empowers smarter research.
Scopus, the leading abstract and citation database of research literature, contains over 73m records across 24,000 journals, sourced from more than 5,000 publishers.
The machine-learning capability of Reaxys® enables the chemistry of drug discovery and materials innovation for over 320 pharma innovators, 140 chemical companies and 470 universities..
Mendeley enables over 11 million users worldwide, from undergraduates to professionals, to organize, write, collaborate and promote their research.
ClinicalKey provides over 490 clinical overviews that gives quick clinical answers and summaries; over 4m images and 51,000 medical and surgical videos in a single, fully integrated site.
Sherpath provides highly focused, personalized and adaptive learning paths for over 33,000 users at more than 400 institutions.
SciVal offers insights into the research performance of over 10,000 research institutions.
With over 70 million publications from 5,000 international publishers, Scopus allows researchers to track, analyze and visualize the world's research output.
Our Elsevier products are used at more than 25,000 academic and government institutions around the world.
Elsevier’s Clinical Solutions are used in 9 of the top 10 pharmacies* in the United States; 97% of the top 100 health systems (ranked by bed count) use at least one of Elsevier’s Clinical Solutions.
Via Oncology helps to improve patient outcomes and provides clinical pathways delivering personalized, evidence-based guidance at the point of care. Via Oncology's Network in North America serves 2,300 cancer physicians.
*Pharmacies includes both retail pharmacy chains and mail-order pharmacies. Source: Drug Channels Institute data.
Our tools are designed to put users in control. They enable faster ways of working, manage complexity and free up time to focus on goals. And users can see how recommendations have been reached.
Throughout Elsevier, we share the research community's belief in what science can achieve.
Many of our people began their careers in science or medicine, and we work with a worldwide network of editors, authors and specialists, covering hundreds of disciplines.
Elsevier has 140 years of experience in curation and verification.
editorial board members and more than 20,000 editors in academia
and over 1.3m reviewers covering hundreds of disciplines
A founding partner and leading contributor.
Elsevier is one of the 6 founding partners of Research4Life. With over 80,000 peer-reviewed resources, R4L has become the primary means of access to research for the majority of users in developing countries. Elsevier provides a quarter of that research, with approximately 3,000 Elsevier journals and 20,000 eBooks as part of its corporate responsibility program. In 2018, there were over 1.8m Research4Life downloads from ScienceDirect.
Collaborating closely with the community means we can respond quickly to genuine needs faced by those in the field. And it allows us to think ahead and address challenges science and medicine may face in the future.
Elsevier believes in making every part of the research lifecycle simpler, more connected and more transparent.
It’s your choice
We offer a mix of open access and subscription models to reflect the different ways authors around the world choose to publish articles. And no matter how an Elsevier journal is funded, the same guarantee of high quality, trustworthy information applies.
All of our journals offer a free, green open access option (after an embargo). Every year, we actively make over 45,000 subscription articles available green open access - more than any other publisher.
Over 85% of our journals offer the option to publish open access and make an article permanently available, immediately, at a price below industry average while delivering above-average quality.
As technology and data bring further change, there will be an even greater need to look at how the system that supports science can be improved. We are determined to lead the way and work with the community to develop solutions that achieve this mission.
Elsevier is where you are to support you.
Ultimately, enhancing the system that underpins science and medicine will help researchers and clinicians solve the 21st century's most challenging problems.